Merck drug Janumet XR gains regulatory approval in Korea

Published: 2013-10-14 06:56:00

Updated: 2013-10-14 06:56:00

MSD Korea announced Thursday that the Ministry of Food and Drug Safety (MFDS) has recently approved Janumet XR (sitagliptin and metformin hydrochloride (HCl) extended-release) tablets, a new treatment for type 2 diabetes that combines sitagliptin, which is the active component of Janumet (sitagli...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK